Consensus criteria for sensitive detection of minimal neuroblastoma cells in bone marrow, blood and stem cell preparations by immunocytology and QRT-PCR: recommendations by the International Neuroblastoma Risk Group Task Force

This publication has 85 references indexed in Scilit:

• The International Neuroblastoma Risk Group (INRG) Staging System: An INRG Task Force Report
  Journal of Clinical Oncology, 2009
• The International Neuroblastoma Risk Group (INRG) Classification System: An INRG Task Force Report
  Journal of Clinical Oncology, 2009
• Exploiting Gene Expression Profiling to Identify Novel Minimal Residual Disease Markers of Neuroblastoma
  Clinical Cancer Research, 2008
• mRNAs of tyrosine hydroxylase and dopa decarboxylase but not of GD2 synthase are specific for neuroblastoma minimal disease and predicts outcome for children with high‐risk disease when measured at diagnosis
  International Journal of Cancer, 2008
• Minimal disease monitoring by QRT–PCR: guidelines for identification and systematic validation of molecular markers prior to evaluation in prospective clinical trials
  The Journal of Pathology, 2008
• Metastasis: recent discoveries and novel treatment strategies
  Published by Elsevier ,2007
• Cyclin D1, a Novel Molecular Marker of Minimal Residual Disease, in Metastatic Neuroblastoma
  The Journal of Molecular Diagnostics, 2007
• Standardisation of operating procedures for the detection of minimal disease by QRT-PCR in children with neuroblastoma: Quality assurance on behalf of SIOPEN-R-NET
  European Journal Of Cancer, 2007
• Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2^−ΔΔC_T Method
  Methods, 2001
• Early clinical evaluation of neuroblastoma cell detection by reverse transcriptase-polymerase chain reaction (RT-PCR) for tyrosine hydroxylase mRNA
  European Journal Of Cancer, 1995